drugset
drugset / Trial / NCT07431866

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

NCT07431866 ↗

Phase 1 Completed 41 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.

Timeline

Start
2026-03-18
Primary completion
2026-06-11
Completion
2026-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified — Oral
Subject MK-2828 Unknown — Oral
Subject Rosuvastatin Small molecule — Oral

Indications

No indication recorded.